353 related articles for article (PubMed ID: 23136410)
41. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.
Citraro R; Leo A; Constanti A; Russo E; De Sarro G
Pharmacol Res; 2016 May; 107():333-343. PubMed ID: 27049136
[TBL] [Abstract][Full Text] [Related]
42. mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia.
Nguyen LH; Brewster AL; Clark ME; Regnier-Golanov A; Sunnen CN; Patil VV; D'Arcangelo G; Anderson AE
Epilepsia; 2015 Apr; 56(4):636-46. PubMed ID: 25752454
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of mammalian target of rapamycin with rapamycin reverses hypertrophic cardiomyopathy in mice with cardiomyocyte-specific knockout of PTEN.
Xu X; Roe ND; Weiser-Evans MC; Ren J
Hypertension; 2014 Apr; 63(4):729-39. PubMed ID: 24446058
[TBL] [Abstract][Full Text] [Related]
44. Seizure-dependent mTOR activation in 5-HT neurons promotes autism-like behaviors in mice.
McMahon JJ; Yu W; Yang J; Feng H; Helm M; McMahon E; Zhu X; Shin D; Huang Y
Neurobiol Dis; 2015 Jan; 73():296-306. PubMed ID: 25315683
[TBL] [Abstract][Full Text] [Related]
45. Mammalian target of rapamycin and tuberous sclerosis complex.
Wataya-Kaneda M
J Dermatol Sci; 2015 Aug; 79(2):93-100. PubMed ID: 26051878
[TBL] [Abstract][Full Text] [Related]
46. Neurovascular Development in
Dusing M; LaSarge CL; White A; Jerow LG; Gross C; Danzer SC
eNeuro; 2023 Feb; 10(2):. PubMed ID: 36759189
[TBL] [Abstract][Full Text] [Related]
47. Neuronal and glia abnormalities in Tsc1-deficient forebrain and partial rescue by rapamycin.
Carson RP; Van Nielen DL; Winzenburger PA; Ess KC
Neurobiol Dis; 2012 Jan; 45(1):369-80. PubMed ID: 21907282
[TBL] [Abstract][Full Text] [Related]
48. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target.
Galanopoulou AS; Gorter JA; Cepeda C
Epilepsia; 2012 Jul; 53(7):1119-30. PubMed ID: 22578218
[TBL] [Abstract][Full Text] [Related]
49. Development and characterization of NEX- Pten, a novel forebrain excitatory neuron-specific knockout mouse.
Kazdoba TM; Sunnen CN; Crowell B; Lee GH; Anderson AE; D'Arcangelo G
Dev Neurosci; 2012; 34(2-3):198-209. PubMed ID: 22572802
[TBL] [Abstract][Full Text] [Related]
50. Unrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase.
Das F; Ghosh-Choudhury N; Dey N; Mandal CC; Mahimainathan L; Kasinath BS; Abboud HE; Choudhury GG
J Biol Chem; 2012 Feb; 287(6):3808-22. PubMed ID: 22184110
[TBL] [Abstract][Full Text] [Related]
51. Role of the mTOR signaling pathway in epilepsy.
Meng XF; Yu JT; Song JH; Chi S; Tan L
J Neurol Sci; 2013 Sep; 332(1-2):4-15. PubMed ID: 23773767
[TBL] [Abstract][Full Text] [Related]
52. PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex.
Alves MM; Fuhler GM; Queiroz KC; Scholma J; Goorden S; Anink J; Spek CA; Hoogeveen-Westerveld M; Bruno MJ; Nellist M; Elgersma Y; Aronica E; Peppelenbosch MP
Sci Rep; 2015 Sep; 5():14534. PubMed ID: 26412398
[TBL] [Abstract][Full Text] [Related]
53. Selective activation of mTORC1 signaling recapitulates microcephaly, tuberous sclerosis, and neurodegenerative diseases.
Kassai H; Sugaya Y; Noda S; Nakao K; Maeda T; Kano M; Aiba A
Cell Rep; 2014 Jun; 7(5):1626-1639. PubMed ID: 24857653
[TBL] [Abstract][Full Text] [Related]
54. The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex.
Zhang B; Zou J; Han L; Beeler B; Friedman JL; Griffin E; Piao YS; Rensing NR; Wong M
Epilepsia; 2018 Sep; 59(9):1796-1806. PubMed ID: 30079598
[TBL] [Abstract][Full Text] [Related]
55. Linking tuberous sclerosis complex, excessive mTOR signaling, and age-related neurodegeneration: a new association between TSC1 mutation and frontotemporal dementia.
Olney NT; Alquezar C; Ramos EM; Nana AL; Fong JC; Karydas AM; Taylor JB; Stephens ML; Argouarch AR; Van Berlo VA; Dokuru DR; Sherr EH; Jicha GA; Dillon WP; Desikan RS; De May M; Seeley WW; Coppola G; Miller BL; Kao AW
Acta Neuropathol; 2017 Nov; 134(5):813-816. PubMed ID: 28828560
[No Abstract] [Full Text] [Related]
56. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice.
Feliciano DM; Su T; Lopez J; Platel JC; Bordey A
J Clin Invest; 2011 Apr; 121(4):1596-607. PubMed ID: 21403402
[TBL] [Abstract][Full Text] [Related]
57. Synaptic hyperexcitability of cytomegalic pyramidal neurons contributes to epileptogenesis in tuberous sclerosis complex.
Wu X; Sosunov AA; Lado W; Teoh JJ; Ham A; Li H; Al-Dalahmah O; Gill BJA; Arancio O; Schevon CA; Frankel WN; McKhann GM; Sulzer D; Goldman JE; Tang G
Cell Rep; 2022 Jul; 40(3):111085. PubMed ID: 35858542
[TBL] [Abstract][Full Text] [Related]
58. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
MacKeigan JP; Krueger DA
Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
[TBL] [Abstract][Full Text] [Related]
59. Tuberous sclerosis complex.
Hasbani DM; Crino PB
Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
[TBL] [Abstract][Full Text] [Related]
60. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.
McDaniel SS; Wong M
Neurosci Lett; 2011 Jun; 497(3):231-9. PubMed ID: 21354266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
